暂无分享,去创建一个
P. Lebranchu | G. Le Meur | J. Ducloyer | F. Billaud | M. Weber
[1] Kathleen A. Marshall,et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.